Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.Plos One|October 25, 2016
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment FailureJun Itakura, Masayuki Kurosaki, Chitomi Hasebe, et al.Journal of Medical Virology|June 25, 2021
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study GroupToshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, et al.Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.Plos One|April 17, 2018
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study GroupToshie Mashiba, Kouji Joko, Masayuki Kurosaki, et al.Journal of Viral Hepatitis|May 13, 2022
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study GroupToshie Mashiba, Kouji Joko, Masayuki Kurosaki, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 2, 2018
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study GroupTakehiro Akahane, Masayuki Kurosaki, Jun Itakura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 12, 2019
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study GroupToshie Mashiba, Kouji Joko, Masayuki Kurosaki, et al.Pageof 4